TNF and juvenile idiopathic arthritis: Adalimumab is a fully human anti-TNF antibody that is approved for use in moderate to severe polyarticular JIA in patients ≥4 years of age in the US, EU, and Japan [4–6], and as of February 2013, adalimumab was also approved in EU for use in patients aged 2 to <4 years old [6].